Cargando…
In Vivo Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus
G-protein coupled receptor 119 (GPR119) has emerged as a promising new target for the treatment of type 2 diabetes mellitus. The expression of GPR119 on the pancreatic B cells and intestinal L cells provides a unique opportunity for a single drug to promote insulin and GLP-1 secretion. In this study...
Autores principales: | Kim, So Ra, Kim, Dae-Hoon, Park, Soo Hyun, Kim, Young Seok, Kim, Chun Hwa, Ha, Tae-Young, Yang, Jin, Rhee, Jae-Keol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872231/ https://www.ncbi.nlm.nih.gov/pubmed/24386644 http://dx.doi.org/10.1155/2013/269569 |
Ejemplares similares
-
HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies
por: Kim, SoRa, et al.
Publicado: (2014) -
GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2018) -
Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy
por: Im, Ji Hye, et al.
Publicado: (2022) -
Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16
por: Tyurenkov, Ivan N., et al.
Publicado: (2018) -
Oleoylethanolamide Exhibits GPR119-Dependent Inhibition of Osteoclast Function and GPR119-Independent Promotion of Osteoclast Apoptosis
por: Kim, Hyun-Ju, et al.
Publicado: (2020)